John Harris

Company: Alys Pharmaceutical

Job title: Chief Innovation Officer

Seminars:

Achieving Durable Regimentation in Vitiligo Through Novel Targets & New Modalities 11:20 am

Vitiligo is an autoimmune disease of the skin with significant unmet medical need Vitiligo is driven by immune signaling through IFNg, and therapies that target this pathway show promise as effective new treatments Relapse occurs in up to 40% of vitiligo patients after stopping therapy and this is due to autoreactive resident memory T cells…Read more

day: Day One AM